Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safusidenib - AnHeart Therapeutics

Next Previous
Drug Profile

Safusidenib - AnHeart Therapeutics

Alternative Names: AB-218; DS-1001; DS-1001b

Latest Information Update: 29 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company; National Cancer Center (Tokyo)
  • Developer AnHeart Therapeutics; Daiichi Sankyo Company; National Cancer Center (Tokyo)
  • Class Alkenes; Antineoplastics; Carboxylic acids; Chlorobenzenes; Fluorinated hydrocarbons; Indoles; Isoxazoles; Ketones; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glioma
  • No development reported Acute myeloid leukaemia; Chondrosarcoma; Solid tumours
  • Discontinued Cholangiocarcinoma

Most Recent Events

  • 17 Jul 2026 Nuvation Bio plans a phase III trial for Glioma (First-line therapy, Recurrent) (PO) in March 2027 (NCT07712757)
  • 17 Jul 2026 Discontinued - Phase-I for Cholangiocarcinoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (Nuvation Bio pipeline, July 2026)
  • 14 Jul 2026 Nuvation Bio plans a phase II trial for Glioma (Second-line therapy or greater) in March 2027 (PO) (NCT07703436)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top